1. Scrip

B+L/Novaliq Hope Miebo Can Stand Out In Crowded Dry Eye Field

Big Week For Bausch As Court Ruling Could Benefit Planned Spinoff

 
• By Alaric DeArment

The companies got US FDA approval for the drug, which they said is the only approved medicine that targets tear evaporation rather than tear production, though its mechanism is not fully understood.

Bausch + Lomb and Novaliq announced the approval of Miebo in dry eye disease • Source: Shutterstock

Bausch + Lomb Corporation and Novaliq GmbH hope to stand out in the crowded field of dry eye disease (DED) with their newly US Food and Drug Administration-approved Miebo (perfluorohexyloctane) based on its mechanism of action and a unique claim of direct effect on tear evaporation.

The commercial effort could be helped by Bausch + Lomb parent company Bausch Health Companies Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.